Pbx 2 Inhibitors
Pbx2 inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of pre-B-cell leukemia homeobox 2 (Pbx2), a transcription factor that plays a crucial role in regulating gene expression during development. Pbx2 belongs to the TALE (three amino acid loop extension) family of homeodomain proteins and acts as a cofactor for other homeodomain proteins, such as Hox proteins. Pbx2 influences various cellular processes by forming heterodimeric or multimeric complexes with other transcription factors, binding to DNA, and regulating the transcription of genes involved in cell differentiation, growth, and development. Pbx2 inhibitors function by disrupting these protein-DNA or protein-protein interactions, thus modulating the transcriptional activity of genes regulated by Pbx2.
The chemical structure of Pbx2 inhibitors is typically engineered to interfere with the DNA-binding domain of Pbx2 or its interaction surfaces with other transcription factors. These inhibitors may work by binding to the Pbx2 protein, preventing it from forming complexes with its partners, or by altering the conformation of Pbx2, hindering its ability to bind to target DNA sequences. Structure-based drug design and high-throughput screening techniques are commonly used to identify and optimize small molecules or peptide-based compounds that effectively inhibit Pbx2 function. Through the use of these inhibitors, researchers can investigate the specific roles of Pbx2 in regulating gene networks and its impact on developmental pathways. Additionally, Pbx2 inhibitors are valuable tools for studying how transcription factor dynamics affect cellular differentiation and lineage specification, helping to unravel the intricate mechanisms of transcriptional regulation in various biological contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine | 1032900-25-6 | sc-505041 | 1 mg | $230.00 | ||
Also called Ceritinib, this compound serves as a direct inhibitor of Pbx2 by targeting the ALK signaling pathway. As an ALK inhibitor, Ceritinib interferes with ALK activation, disrupting downstream signaling events that involve Pbx2. Specifically, ALK activation promotes Pbx2 expression, and Ceritinib, by inhibiting ALK, can modulate the ALK/Pbx2 axis, resulting in reduced Pbx2 levels. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib acts as a direct inhibitor of Pbx2 through the MEK/ERK signaling pathway. By inhibiting MEK, Selumetinib disrupts the phosphorylation cascade that regulates Pbx2 expression. This direct inhibition occurs at the transcriptional level, where Selumetinib interferes with the activation of transcription factors involved in Pbx2 gene expression, resulting in decreased mRNA levels and subsequent downregulation of Pbx2 protein expression. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib serves as an indirect inhibitor of Pbx2 by targeting the Src family kinase signaling pathway. By inhibiting Src family kinases, Dasatinib interferes with downstream signaling events that regulate Pbx2 expression. Src family kinases are involved in the activation of transcription factors related to Pbx2, and Dasatinib, by inhibiting these kinases, can modulate the Src/Pbx2 axis, resulting in reduced Pbx2 levels. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib acts as a direct inhibitor of Pbx2 through the RAF/MEK/ERK signaling pathway. By inhibiting RAF, Sorafenib disrupts the phosphorylation cascade that regulates Pbx2 expression. This direct inhibition occurs at the transcriptional level, where Sorafenib interferes with the activation of transcription factors involved in Pbx2 gene expression, resulting in decreased mRNA levels and subsequent downregulation of Pbx2 protein expression. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib serves as an indirect inhibitor of Pbx2 by targeting the JAK/STAT signaling pathway. By inhibiting JAK, Ruxolitinib interferes with downstream signaling events that regulate Pbx2 expression. JAK activation is involved in the phosphorylation cascade that influences transcription factors related to Pbx2, and Ruxolitinib, by inhibiting JAK, can modulate the JAK/Pbx2 axis, resulting in reduced Pbx2 levels. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib serves as an indirect inhibitor of Pbx2 by targeting the ABL signaling pathway. By inhibiting ABL, Imatinib interferes with downstream signaling events that regulate Pbx2 expression. ABL activation is involved in the phosphorylation cascade that influences transcription factors related to Pbx2, and Imatinib, by inhibiting ABL, can modulate the ABL/Pbx2 axis, resulting in reduced Pbx2 levels. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib serves as a direct inhibitor of Pbx2 through the receptor tyrosine kinase (RTK) signaling pathway. By inhibiting multiple RTKs, Sunitinib disrupts downstream signaling events that involve Pbx2. RTK activation promotes Pbx2 expression, and Sunitinib, by inhibiting RTKs, can modulate the RTK/Pbx2 axis, resulting in reduced Pbx2 levels. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib acts as a direct inhibitor of Pbx2 through the MEK/ERK signaling pathway. By inhibiting MEK, Trametinib disrupts the phosphorylation cascade that regulates Pbx2 expression. This direct inhibition occurs at the transcriptional level, where Trametinib interferes with the activation of transcription factors involved in Pbx2 gene expression, resulting in decreased mRNA levels and subsequent downregulation of Pbx2 protein expression. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib serves as a direct inhibitor of Pbx2 through the EGFR signaling pathway. By inhibiting EGFR, Erlotinib disrupts the phosphorylation cascade that regulates Pbx2 expression. This direct inhibition occurs at the transcriptional level, where Erlotinib interferes with the activation of transcription factors involved in Pbx2 gene expression, resulting in decreased mRNA levels and subsequent downregulation of Pbx2 protein expression. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib serves as a direct inhibitor of Pbx2 through the ABL signaling pathway. By inhibiting ABL, Nilotinib disrupts the phosphorylation cascade that regulates Pbx2 expression. This direct inhibition occurs at the transcriptional level, where Nilotinib interferes with the activation of transcription factors involved in Pbx2 gene expression, resulting in decreased mRNA levels and subsequent downregulation of Pbx2 protein expression. | ||||||